查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
仿製藥市場-全球行業規模、份額、趨勢、機會和預測，2018-2028 年，按類型、按應用、按藥物輸送、按形式、按來源、按分銷渠道、按地區、按競爭對手
市場調查報告書
商品編碼
1266841

仿製藥市場-全球行業規模、份額、趨勢、機會和預測，2018-2028 年，按類型、按應用、按藥物輸送、按形式、按來源、按分銷渠道、按地區、按競爭對手

Generic Drugs Market- Global Industry Size, Share, Trends, Opportunity and Forecast, 2018-2028F By Type, By Application, By Drug Delivery, By Form, By Source, By Distribution Channel, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 312 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

仿製藥市場預計到 2022 年價值 4160.6 億美元，並在預測期內以 6.51% 的複合年增長率進一步增長，這是由於對仿製藥的需求不斷增長。

仿製藥市場在未來幾年將繼續增長，原因包括慢性病患者增多、專利到期、對低價藥物的需求增加、仿製藥易於獲得以及政府支持仿製藥上市預計將繼續增長。

慢性病患病率增加

由於遺傳、環境、行為和生理因素等長期疾病，慢性病患病率上升將推動預測期內的市場增長。 慢性病影響全世界所有年齡組。 此外，慢性阻塞性肺病和哮喘等慢性呼吸系統疾病以及惡性腫瘤、糖尿病和心血管疾病等非傳染性疾病是最常見的疾病，這將在預測期內進一步增加對仿製藥的需求。 同樣，快速城市化、不健康生活方式的全球化和人口老齡化等主要因素預計將在預測期內推動市場增長。 糖尿病、癌症和心血管疾病等慢性病的全球患病率正在迅速增加。 因此，對負擔得起的有效治療的需求不斷增長，推動了仿製藥市場的增長。 換句話說，患者更喜歡仿製藥，因為需求會隨著時間的推移而增加。 根據全國健康訪談調查，美國 51.8% 的成年人患有一種慢性病，約 27% 的人患有多種慢性病。 據世界衛生組織稱，全世界每年有 3800 萬人受到慢性病的影響。 據世界衛生組織稱，慢性病導致約 4100 萬人死亡，佔全球所有死亡人數的 71%。 其中，1790 萬人死於心髒病，930 萬人死於癌症，410 萬人死於呼吸系統疾病，150 萬人死於糖尿病。 此外，吸煙、飲酒增加和缺乏鍛煉等其他因素也影響了市場增長。

慢性病會對仿製藥市場的增長產生重大影響。 慢性病是一種長期存在的疾病，需要持續的醫療護理，而且通常需要使用藥物。 慢性病的例子包括糖尿病、高血壓、關節炎和心髒病。 仿製藥通常比品牌產品便宜，這使它們成為許多慢性病患者的有吸引力的選擇。 這是因為仿製藥製造商不必投入昂貴的研發和市場開發，以較低的價格形式轉嫁給消費者。 世界衛生組織報告稱，慢性病是全球死亡的主要原因，佔 2019 年所有死亡人數的 71%。 然而，根據世界衛生組織 (WHO) 的《2021 年全球吸煙流行趨勢報告》，全球吸煙流行率將從 2000 年的 27% 下降到 2020 年的 20%。我來了。

對仿製藥的需求不斷增長

品牌藥的專利到期是全球仿製藥市場的增長動力，為創新創造了機會，並使患者更容易獲得藥物。 當品牌藥的專利到期時，它會對全球仿製藥市場產生重大影響。 一旦專利到期，其他製造商可以生產和銷售該藥物的仿製藥，通常價格低於品牌藥。 這為仿製藥製造商進入市場並為消費者提供更實惠的選擇創造了機會。 因此，對仿製藥的需求將增加，從而推動仿製藥市場的增長。 例如，西妥昔單抗是一種表皮生長因子受體抑製劑，用於治療轉移性結直腸癌和頭頸癌。 在歐洲，它由 Bristol-Myers Squibb 和 Eli Lilly 根據 2018 年到期的專利生產。 因此，許多市場參與者有望提供製造後續產品的機會。

除了競爭加劇和價格下降之外，專利到期還可能導致仿製藥市場的創新。 仿製藥製造商可能會開發新的藥物配方和給藥方法，以提高藥物的療效和患者的便利性。

但是，請務必記住，並非所有藥物在專利到期後都會對仿製藥市場產生重大影響。 根據藥物的不同，仿製藥製造商生產它可能無利可圖，或者品牌藥可能具有仿製藥無法輕易複製的獨特特性。 此外，FDA 對加速生物仿製藥開發的支持正在鼓勵製造商專注於他們的開發。 一旦品牌藥的專利到期，仿製藥製造商就可以進入市場並生產價格較低的藥物。 然而，專利糾紛和原藥製造商延遲競爭的策略可能會延遲仿製藥的可用性。

對低成本藥物的需求增加

低價仿製藥將對全球仿製藥市場產生重大影響，使患者更能負擔得起藥品，減輕醫療保健系統的財務負擔，並刺激製藥行業的創新。要做。 仿製藥通常比品牌藥便宜，這使它們成為患者更負擔得起的選擇。 獲得廉價藥品的機會有限，特別是在發展中國家，因此低價仿製藥的可用性會對醫療保健系統產生重大影響。 因此，這些地區對仿製藥的需求增加，這有助於全球仿製藥市場的增長。 仿製藥節省的成本也有利於醫療保健提供者、保險公司和政府。 醫療保健提供者可以通過使用仿製藥降低患者的治療成本，改善獲得護理的機會，並減輕患者及其家人的經濟負擔。

此外，為了降低成本，低價仿製藥還可以鼓勵製藥行業的創新。 隨著公司競相生產最便宜和最有效的仿製藥，他們可能會在研發方面投入更多資金，以改進藥物配方、給藥和療效。 2021 年 12 月，美國 FDA 批准了 Gilenya 的第一個仿製藥，這是一種用於治療多發性硬化症的藥物。

近期發展

  • 2021 年 11 月，印度政府宣布了一項新政策，旨在降低成本並促進仿製藥在該國的使用。
  • 2021 年 9 月，發表在《美國醫學會雜誌》上的一項研究發現，在美國使用仿製藥可為糖尿病患者節省大量費用。
  • 2021 年 8 月，美國 FDA 批准了 Advair Discus 的第一個仿製藥，這是一種用於治療哮喘和慢性阻塞性肺疾病 (COPD) 的藥物。
  • 2021 年 7 月，世界衛生組織 (WHO) 發起了一項新舉措，旨在擴大仿製藥的普及範圍並降低全球的藥品成本。

可自定義

根據市場數據，TechSci Research 根據公司的具體需求提供定制服務。 該報告可以定制為：

公司信息

  • 對其他市場參與者（最多 5 家公司）進行深入分析和概況分析

內容

第 1 章概述

  • 市場定義
  • 市場範圍
    • 目標市場
    • 研究目標年份
    • 主要市場細分

第二章研究方法論

  • 調查目的
  • 基線調查方法
  • 主要行業合作夥伴
  • 主要協會和次要信息
  • 調查方法
  • 數據三角測量和驗證
  • 假設和限制

第 3 章執行摘要

  • 市場概覽
  • 主要市場細分概述
  • 主要市場參與者概覽
  • 主要地區/國家概覽
  • 市場驅動因素、挑戰和趨勢

第 4 章 VOC（客戶之聲）

第 5 章仿製藥的全球市場展望

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 按類型（低分子仿製藥和生物仿製藥）
    • 按應用（心血管疾病、糖尿病、神經病學、癌症、抗炎性疾病等）
    • 通過給藥（口服、局部、腸胃外、其他）
    • 按劑型（片劑、膠囊劑、注射劑等）
    • 按供應商分類（內部製造組織與合同製造組織之間的區別）
    • 按分銷渠道（醫院藥店、零售藥店、在線藥店、其他）
    • 按公司分類（2022 年）
    • 按地區
  • 市場地圖
    • 按類型
    • 通過申請
    • 通過給藥
    • 按表格
    • 按來源
    • 按分銷渠道
    • 按地區

第六章北美仿製藥市場展望

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 按類型
    • 通過申請
    • 通過給藥
    • 按表格
    • 按來源
    • 按分銷渠道
    • 按國家
  • 北美：國家/地區分析
    • 美國
    • 墨西哥
    • 加拿大

第七章歐洲仿製藥市場前景

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 按類型
    • 通過申請
    • 通過給藥
    • 按表格
    • 按來源
    • 按分銷渠道
    • 按國家
  • 歐洲：國家分析
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙

第八章亞太仿製藥市場展望

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 按類型
    • 通過申請
    • 通過給藥
    • 按表格
    • 按來源
    • 按分銷渠道
    • 按國家
  • 亞太地區：國家/地區分析
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳大利亞

第9章南美仿製藥市場展望

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 按類型
    • 通過申請
    • 通過給藥
    • 按表格
    • 按來源
    • 按分銷渠道
    • 按國家
  • 南美洲：：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第 10 章中東和非洲仿製藥市場展望

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 按類型
    • 通過申請
    • 通過給藥
    • 按表格
    • 按來源
    • 按分銷渠道
    • 按國家
  • MEA：國家分析
    • 南非仿製藥
    • 沙特阿拉伯仿製藥
    • 阿聯酋仿製藥
    • 科威特仿製藥

第 11 章市場動態

  • 主持人
  • 做

第12章市場趨勢與發展

  • 近期發展狀況
  • 併購
  • 產品發布

第 13 章仿製藥全球市場：SWOT 分析

第 14 章波特的五力分析

  • 行業競爭
  • 新進入的可能性
  • 供應商的力量
  • 客戶力量
  • 替代品的威脅

第15章競爭格局

  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH（Novartis AG）
  • Viatris Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Fresenius Kabi AG
  • STADA Arzneimittel AG
  • Aurobindo Pharma Limited
  • Dr Reddy's Laboratories Ltd
  • Cipla Ltd
  • Novo Nordisk A/S
  • Abbott Laboratories Inc.
  • Endo Pharmaceuticals Inc.
  • Sanofi SA
  • Aspen Pharmacare Holdings Limited
  • Lupin Limited

第16章 戰略建議

Product Code: 7332

Generic Drugs Market was valued at USD 416.06 billion in 2022 and is further anticipated to grow at a CAGR of 6.51%, during the forecast period, owing to rising demand for generic drugs. The Generic Drugs market is expected to continue growing in the coming years, driven by factors such as the increasing prevalence of chronic diseases, expiration of patent drugs, growing demand for low-cost drugs, and easy accessibility and supportive governments for allowing generic drugs in the market.

The increasing aging population, along with the growing demand for low-cost generic drugs, will further drive the growth of the market during the forecast period. As consumers become more aware of the cost savings and efficacy of generic drugs, they are more likely to choose them over branded drugs which is a factor expected to drive the growth of the market during the forecast period. Generic drugs are used to treat a wide range of medical conditions, just like their branded counterparts. They contain the same active ingredients and are equivalent in strength, dosage, safety, and effectiveness.

Advancements in generic drugs have also contributed to the growth of the Generic Drugs market. Some generic drugs are now being developed as combination therapies, which combine two or more drugs into a single pill or other delivery systems. This can increase patient compliance and reduce the overall cost of treatment.

While the Generic Drugs market is growing rapidly, there are also several challenges that are impeding its growth. One of the biggest challenges the global generic drugs market is facing is ensuring the quality of generic drugs is the same as branded drugs. Others are Regulatory hurdles for approval of the generic drugs along with pricing pressures. Patent litigation is also a challenge that will hamper the growth of the global generic drugs market.

Growing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases due to long-term illnesses such as genetic, environmental, behavioral, and physiological factors will drive the growth of the market during the forecast period. Chronic diseases impact all ages across the globe. Also, non-communicable diseases such as chronic respiratory diseases such as COPD, asthma, malignancies and, diabetes, cardiovascular diseases are the most common diseases, which will further increase the demand for generic drugs in the forecast period. Similarly, some major factors like rapid urbanization, globalization of leading unhealthy lifestyle, and the growing aging population is expected to drive the growth of the market during the forecast period. The global prevalence of chronic diseases such as diabetes, cancer, and cardiovascular diseases is increasing rapidly. As a result, there is a growing demand for affordable and effective treatments, which has driven the growth of the generic drugs market. So, patients prefer generic drugs as demand grows with time. According to the National Health Interview Survey, 51.8% of U.S adults have one chronic disease, and approx. 27% of people are suffering from several chronic diseases. Per year, 38 million people are affected because of chronic diseases across the globe, according to WHO. According to WHO, chronic diseases affect almost 41 million people, which is equivalent to 71% of all deaths globally; among these, 17.9 million deaths are caused for heart disease, 9.3 million deaths are caused due to cancer, and 4.1 million deaths due to respiratory diseases, 1.5 million deaths due to diabetes per year. Additionally, other factors are also influencing the growth of the market, such as exposure to the use of tobacco, increasing consumption of alcohol, and physical inactivity.

Chronic diseases can have a significant impact on the growth of the generic drugs market. Chronic diseases are long-lasting medical conditions that require ongoing medical attention and often require the use of medication. Examples of chronic diseases include diabetes, hypertension, arthritis, and heart disease. Generic drugs are an attractive option for many patients with chronic diseases because they are typically less expensive than their branded counterparts. This is because generic drug manufacturers do not have to invest in expensive research and development or marketing campaigns, which can be passed on to consumers in the form of lower prices. The WHO also reports that chronic diseases are the leading cause of death worldwide, accounting for 71% of all deaths in 2019. However, according to the World Health Organization's 2021 Global Report on Trends in Prevalence of Tobacco Smoking, the global prevalence of smoking has decreased from 27% in 2000 to 20% in 2020.

Growing Demand for Generic Drugs

The expiration of patents for branded drugs is a major driver of growth in the global generic drugs market, creating opportunities for innovation and making medications more accessible to patients. The expiration of patents for branded drugs can have a significant impact on the global generic drugs market. When a patent expires, it allows other manufacturers to produce and sell generic versions of the drug, often at a lower cost than the branded drug. This creates an opportunity for generic drug manufacturers to enter the market and offer more affordable options to consumers. As a result, the demand for generic drugs increases, driving growth in the generic drugs market. For example, Cetuximab is an epidermal growth factor receptor inhibitor that is used for the treatment of metastatic colorectal cancer and head and neck cancer. It is manufactured under the patent by Bristol-Myers Squibb and Eli Lily Company in Europe, and it expired in 2018. It is thus expected to provide an opportunity for a large number of market players to manufacture its generic version.

In addition to increasing competition and lowering prices, the expiration of patents can also lead to innovation in the generic drugs market. Generic drug manufacturers may develop new formulations or delivery methods for the drug, improving its efficacy and convenience for patients.

However, it is important to note that not all drugs have a significant impact on the generic drugs market when their patents expire. Some drugs may not be profitable for generic manufacturers to produce, or the original drug may have unique properties that cannot be easily replicated by a generic version. Additionally, a supportive initiative by the FDA for promoting the development of biosimilars is encouraging manufacturers to focus on its development. As patents on brand-name drugs expire, generic drug manufacturers can enter the market and produce lower-cost versions of the drug. However, the availability of generic drugs can still be delayed if there are patent disputes or if the brand-name manufacturer implements strategies to delay competition.

Growing Demand for Low-Cost Drugs

Low-cost generic drugs have a significant impact on the global generic drugs market, making medications more affordable and accessible to patients, reducing the financial burden on healthcare systems, and driving innovation in the pharmaceutical industry. Generic drugs are typically less expensive than their branded counterparts, which makes them a more affordable option for patients. The availability of low-cost generic drugs can have a major impact on healthcare systems, particularly in developing countries, where access to affordable medications can be limited. This has led to increased demand for generic drugs in these regions, which has, in turn, contributed to the growth of the global generic drugs market. The cost savings associated with generic drugs also benefit healthcare providers, insurance companies, and governments. By using generic drugs, healthcare providers can reduce the cost of treatment for their patients, which can improve access to care and reduce the financial burden on patients and their families.

Additionally, to lower costs, low-cost generic drugs can also drive innovation in the pharmaceutical industry. As companies compete to produce the most affordable and effective generic versions of a drug, they may further invest in research and development to improve the formulation, delivery, and efficacy of the drug. In December 2021, the US FDA approved the first generic version of the drug Gilenya, used to treat multiple sclerosis.

Recent Development

  • In November 2021, the Indian government announced a new policy aimed at reducing the cost of generic drugs and promoting their use in the country.
  • In September 2021, a study published in the Journal of the American Medical Association found that the use of generic drugs can lead to significant cost savings for patients with diabetes in the United States.
  • In August 2021, the US FDA approved the first generic version of the drug Advair Diskus, used to treat asthma and chronic obstructive pulmonary disease (COPD).
  • In July 2021, the World Health Organization (WHO) launched a new initiative aimed at increasing access to generic drugs and reducing the cost of medications worldwide.

Market Segmentation

Global generic drugs market is segmented based on type, application, drug delivery, form, source, distribution channel, and region. Based on type, the market is divided into Small Molecule Generics vs. Biosimilars. Based on application, the market is further segmented into Cardiovascular Diseases, Diabetes, Neurology, Oncology, Anti-Inflammatory Diseases, and Others. Based on drug delivery, the market is differentiated into Oral, Topical, Parenteral, and Others. Based on form, the market is segmented into tablets, Capsules, Injections, and Others. Based on the source, the market is divided into In House vs. Contract Manufacturing Organizations. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others.

Market Players

Teva Pharmaceutical Industries Ltd, Sandoz International GmbH (Novartis AG), Viatris Inc., Sun Pharmaceutical Industries Ltd., Fresenius Kabi AG, STADA Arzneimittel AG, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd, Cipla Ltd, Novo Nordisk A/S, Abbott Laboratories Inc., Endo Pharmaceuticals Inc., Sanofi SA, Aspen Pharmacare Holdings Limited, Lupin Limited, among others, are some of the key players operating in the global Generic Drugs Market.

Report Scope:

In this report, Global Generic Drugs Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Generic Drugs Market, By Type:

  • Small Molecule Generics
  • Biosimilars

Generic Drugs Market, By Application:

  • Cardiovascular Diseases
  • Diabetes
  • Neurology
  • Oncology
  • Anti-Inflammatory Diseases
  • Others

Generic Drugs Market, By Drug Delivery:

  • Oral
  • Topical
  • Parenteral
  • Others

Generic Drugs Market, By Form:

  • Tablet
  • Capsule
  • Injection
  • Others

Generic Drugs Market, By Source:

  • In House
  • Contract Manufacturing Organizations

Generic Drugs Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Generic Drugs Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Colombia
    • Argentina
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the global Generic Drugs market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Generic Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Small Molecule Generics vs Biosimilars)
    • 5.2.2. By Application (Cardiovascular Diseases, Diabetes, Neurology, Oncology, Anti-Inflammatory Diseases, Others)
    • 5.2.3. By Drug Delivery (Oral, Topical, Parenteral, Others)
    • 5.2.4. By Form (Tablet, Capsule, Injection, Others)
    • 5.2.5. By Source (In House vs Contract Manufacturing Organizations)
    • 5.2.6. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
    • 5.2.7. By Company (2022)
    • 5.2.8. By Region
  • 5.3. Market Map
    • 5.3.1. By Type
    • 5.3.2. By Application
    • 5.3.3. By Drug Delivery
    • 5.3.4. By Form
    • 5.3.5. By Source
    • 5.3.6. By Distribution Channel
    • 5.3.7. By Region

6. North America Generic Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Drug Delivery
    • 6.2.4. By Form
    • 6.2.5. By Source
    • 6.2.6. By Distribution Channel
    • 6.2.7. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Generic Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Drug Delivery
        • 6.3.1.2.4. By Form
        • 6.3.1.2.5. By Source
        • 6.3.1.2.6. By Distribution Channel
    • 6.3.2. Mexico Generic Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Drug Delivery
        • 6.3.2.2.4. By Form
        • 6.3.2.2.5. By Source
        • 6.3.2.2.6. By Distribution Channel
    • 6.3.3. Canada Generic Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Drug Delivery
        • 6.3.3.2.4. By Form
        • 6.3.3.2.5. By Source
        • 6.3.3.2.6. By Distribution Channel

7. Europe Generic Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Drug Delivery
    • 7.2.4. By Form
    • 7.2.5. By Source
    • 7.2.6. By Distribution Channel
    • 7.2.7. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Generic Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Drug Delivery
        • 7.3.1.2.4. By Form
        • 7.3.1.2.5. By Source
        • 7.3.1.2.6. By Distribution Channel
    • 7.3.2. United Kingdom Generic Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Drug Delivery
        • 7.3.2.2.4. By Form
        • 7.3.2.2.5. By Source
        • 7.3.2.2.6. By Distribution Channel
    • 7.3.3. France Generic Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Drug Delivery
        • 7.3.3.2.4. By Form
        • 7.3.3.2.5. By Source
        • 7.3.3.2.6. By Distribution Channel
    • 7.3.4. Italy Generic Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Drug Delivery
        • 7.3.4.2.4. By Form
        • 7.3.4.2.5. By Source
        • 7.3.4.2.6. By Distribution Channel
    • 7.3.5. Spain Generic Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Drug Delivery
        • 7.3.5.2.4. By Form
        • 7.3.5.2.5. By Source
        • 7.3.5.2.6. By Distribution Channel

8. Asia-Pacific Generic Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Drug Delivery
    • 8.2.4. By Form
    • 8.2.5. By Source
    • 8.2.6. By Distribution Channel
    • 8.2.7. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Generic Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Drug Delivery
        • 8.3.1.2.4. By Form
        • 8.3.1.2.5. By Source
        • 8.3.1.2.6. By Distribution Channel
    • 8.3.2. Japan Generic Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Drug Delivery
        • 8.3.2.2.4. By Form
        • 8.3.2.2.5. By Source
        • 8.3.2.2.6. By Distribution Channel
    • 8.3.3. South Korea Generic Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Drug Delivery
        • 8.3.3.2.4. By Form
        • 8.3.3.2.5. By Source
        • 8.3.3.2.6. By Distribution Channel
    • 8.3.4. India Generic Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Drug Delivery
        • 8.3.4.2.4. By Form
        • 8.3.4.2.5. By Source
        • 8.3.4.2.6. By Distribution Channel
    • 8.3.5. Australia Generic Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Drug Delivery
        • 8.3.5.2.4. By Form
        • 8.3.5.2.5. By Source
        • 8.3.5.2.6. By Distribution Channel

9. South America Generic Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Drug Delivery
    • 9.2.4. By Form
    • 9.2.5. By Source
    • 9.2.6. By Distribution Channel
    • 9.2.7. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Generic Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Drug Delivery
        • 9.3.1.2.4. By Form
        • 9.3.1.2.5. By Source
        • 9.3.1.2.6. By Distribution Channel
    • 9.3.2. Colombia Generic Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Drug Delivery
        • 9.3.2.2.4. By Form
        • 9.3.2.2.5. By Source
        • 9.3.2.2.6. By Distribution Channel
    • 9.3.3. Argentina Generic Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Drug Delivery
        • 9.3.3.2.4. By Form
        • 9.3.3.2.5. By Source
        • 9.3.3.2.6. By Distribution Channel

10. Middle East and Africa Generic Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Drug Delivery
    • 10.2.4. By Form
    • 10.2.5. By Source
    • 10.2.6. By Distribution Channel
    • 10.2.7. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Generic Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Drug Delivery
        • 10.3.1.2.4. By Form
        • 10.3.1.2.5. By Source
        • 10.3.1.2.6. By Distribution Channel
    • 10.3.2. Saudi Arabia Generic Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Drug Delivery
        • 10.3.2.2.4. By Form
        • 10.3.2.2.5. By Source
        • 10.3.2.2.6. By Distribution Channel
    • 10.3.3. UAE Generic Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Drug Delivery
        • 10.3.3.2.4. By Form
        • 10.3.3.2.5. By Source
        • 10.3.3.2.6. By Distribution Channel
    • 10.3.4. Kuwait Generic Drugs Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type
        • 10.3.4.2.2. By Application
        • 10.3.4.2.3. By Drug Delivery
        • 10.3.4.2.4. By Form
        • 10.3.4.2.5. By Source
        • 10.3.4.2.6. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Generic Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Product Offerings
  • 15.3. Recent Developments
  • 15.4. Financials (As Reported)
  • 15.5. Key Personnel
  • 15.6. SWOT Analysis
    • 15.6.1. Teva Pharmaceutical Industries Ltd.
    • 15.6.2. Sandoz International GmbH (Novartis AG)
    • 15.6.3. Viatris Inc.
    • 15.6.4. Sun Pharmaceutical Industries Ltd.
    • 15.6.5. Fresenius Kabi AG
    • 15.6.6. STADA Arzneimittel AG
    • 15.6.7. Aurobindo Pharma Limited
    • 15.6.8. Dr Reddy's Laboratories Ltd
    • 15.6.9. Cipla Ltd
    • 15.6.10. Novo Nordisk A/S
    • 15.6.11. Abbott Laboratories Inc.
    • 15.6.12. Endo Pharmaceuticals Inc.
    • 15.6.13. Sanofi SA
    • 15.6.14. Aspen Pharmacare Holdings Limited
    • 15.6.15. Lupin Limited

16. Strategic Recommendations

List of Figures

  • Figure 1: Global Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 2: Global Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 3: Global Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 4: Global Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 5: Global Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 6: Global Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 7: Global Generic Drugs Market Share, By Distribution Channel , By Value, 2018-2028F
  • Figure 8: Global Generic Drugs Market Share, By Region, By Value, 2018-2028F
  • Figure 9: Global Generic Drugs Market Share, By Company, By Value, 2022
  • Figure 10: Global Generic Drugs Market Map, By Type, Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 11: Global Generic Drugs Market Map, By Application, Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 12: Global Generic Drugs Market Map, By Drug Delivery , Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 13: Global Generic Drugs Market Map, By Form, Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 14: Global Generic Drugs Market Map, By Source, Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 15: Global Generic Drugs Market Map, By Distribution Channel, Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 16: Global Generic Drugs Market Map, By Region, Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 17: North America Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 18: North America Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 19: North America Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 20: North America Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 21: North America Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 22: North America Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 23: North America Generic Drugs Market Share, By Distribution Channel , By Value, 2018-2028F
  • Figure 24: North America Generic Drugs Market Share, By Country, By Value, 2018-2028F
  • Figure 25: United States Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 26: United States Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 27: United States Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 28: United States Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 29: United States Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 30: United States Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 31: United States Generic Drugs Market Share, By Distribution Channel , By Value, 2018-2028F
  • Figure 32: Canada Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 33: Canada Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 34: Canada Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 35: Canada Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 36: Canada Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 37: Canada Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 38: Canada Generic Drugs Market Share, By Distribution Channel , By Value, 2018-2028F
  • Figure 39: Mexico Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 40: Mexico Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 41: Mexico Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 42: Mexico Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 43: Mexico Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 44: Mexico Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 45: Mexico Generic Drugs Market Share, By Distribution Channel , By Value, 2018-2028F
  • Figure 46: Europe Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 47: Europe Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 48: Europe Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 49: Europe Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 50: Europe Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 51: Europe Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 52: Europe Generic Drugs Market Share, By Distribution Channel , By Value, 2018-2028F
  • Figure 53: Europe Generic Drugs Market Share, By Country, By Value, 2018-2028F
  • Figure 54: Germany Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 55: Germany Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 56: Germany Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 57: Germany Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 58: Germany Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 59: Germany Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 60: Germany Generic Drugs Market Share, By Distribution Channel , By Value, 2018-2028F
  • Figure 61: France Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 62: France Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 63: France Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 64: France Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 65: France Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 66: France Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 67: France Generic Drugs Market Share, By Distribution Channel , By Value, 2018-2028F
  • Figure 68: United Kingdom Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 69: United Kingdom Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 70: United Kingdom Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 71: United Kingdom Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 72: United Kingdom Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 73: United Kingdom Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 74: United Kingdom Generic Drugs Market Share, By Distribution Channel , By Value, 2018-2028F
  • Figure 75: Spain Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 76: Spain Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 77: Spain Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 78: Spain Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 79: Spain Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 80: Spain Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 81: Spain Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 82: Italy Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 83: Italy Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 84: Italy Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 85: Italy Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 86: Italy Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 87: Italy Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 88: Italy Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 89: Asia Pacific Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 90: Asia Pacific Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 91: Asia Pacific Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 92: Asia Pacific Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 93: Asia Pacific Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 94: Asia Pacific Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 95: Asia Pacific Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 96: Asia Pacific Generic Drugs Market Share, By Country, By Value, 2018-2028F
  • Figure 97: China Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 98: China Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 99: China Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 100: China Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 101: China Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 102: China Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 103: China Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 104: India Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 105: India Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 106: India Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 107: India Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 108: India Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 109: India Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 110: India Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 111: Japan Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 112: Japan Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 113: Japan Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 114: Japan Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 115: Japan Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 116: Japan Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 117: Japan Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 118: Australia Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 119: Australia Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 120: Australia Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 121: Australia Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 122: Australia Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 123: Australia Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 124: Australia Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 125: South Korea Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 126: South Korea Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 127: South Korea Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 128: South Korea Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 129: South Korea Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 130: South Korea Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 131: South Korea Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 132: South America Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 133: South America Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 134: South America Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 135: South America Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 136: South America Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 137: South America Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 138: South America Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 139: South America Generic Drugs Market Share, By Country, By Value, 2018-2028F
  • Figure 140: Brazil Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 141: Brazil Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 142: Brazil Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 143: Brazil Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 144: Brazil Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 145: Brazil Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 146: Brazil Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 147: Argentina Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 148: Argentina Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 149: Argentina Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 150: Argentina Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 151: Argentina Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 152: Argentina Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 153: Argentina Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 154: Colombia Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 155: Colombia Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 156: Colombia Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 157: Colombia Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 158: Colombia Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 159: Colombia Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 160: Colombia Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 161: Middle East & Africa Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 162: Middle East & Africa Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 163: Middle East & Africa Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 164: Middle East & Africa Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 165: Middle East & Africa Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 166: Middle East & Africa Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 167: Middle East & Africa Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 168: Middle East & Africa Generic Drugs Market Share, By Country, By Value, 2018-2028F
  • Figure 169: South Africa Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 170: South Africa Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 171: South Africa Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 172: South Africa Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 173: South Africa Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 174: South Africa Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 175: South Africa Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 176: Saudi Arabia Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 177: Saudi Arabia Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 178: Saudi Arabia Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 179: Saudi Arabia Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 180: Saudi Arabia Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 181: Saudi Arabia Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 182: Saudi Arabia Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 183: UAE Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 184: UAE Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 185: UAE Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 186: UAE Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 187: UAE Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 188: UAE Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 189: UAE Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F